Merck
CN
  • A selective orexin-1 receptor antagonist attenuates stress-induced hyperarousal without hypnotic effects.

A selective orexin-1 receptor antagonist attenuates stress-induced hyperarousal without hypnotic effects.

The Journal of pharmacology and experimental therapeutics (2015-01-15)
Pascal Bonaventure, Sujin Yun, Philip L Johnson, Anantha Shekhar, Stephanie D Fitz, Brock T Shireman, Terry P Lebold, Diane Nepomuceno, Brian Lord, Michelle Wennerholm, Jonathan Shelton, Nicholas Carruthers, Timothy Lovenberg, Christine Dugovic
摘要

Orexins (OXs) are peptides produced by perifornical (PeF) and lateral hypothalamic neurons that exert a prominent role in arousal-related processes, including stress. A critical role for the orexin-1 receptor (OX1R) in complex emotional behavior is emerging, such as overactivation of the OX1R pathway being associated with panic or anxiety states. Here we characterize a brain-penetrant, selective, and high-affinity OX1R antagonist, compound 56 [N-({3-[(3-ethoxy-6-methylpyridin-2-yl)carbonyl]-3-azabicyclo[4.1.0]hept-4-yl}methyl)-5-(trifluoromethyl)pyrimidin-2-amine]. Ex vivo receptor binding studies demonstrated that, after subcutaneous administration, compound 56 crossed the blood-brain barrier and occupied OX1Rs in the rat brain at lower doses than standard OX1R antagonists GSK-1059865 [5-bromo-N-({1-[(3-fluoro-2-methoxyphenyl)carbonyl]-5-methylpiperidin-2-yl}methyl)pyridin-2-amine], SB-334867 [1-(2-methyl-1,3-benzoxazol-6-yl)-3-(1,5-naphthyridin-4-yl)urea], and SB-408124 [1-(6,8-difluoro-2-methylquinolin-4-yl)-3-[4-(dimethylamino)phenyl]urea]. Although compound 56 did not alter spontaneous sleep in rats and in wild-type mice, its administration in orexin-2 receptor knockout mice selectively promoted rapid eye movement sleep, demonstrating target engagement and specific OX1R blockade. In a rat model of psychological stress induced by cage exchange, the OX1R antagonist prevented the prolongation of sleep onset without affecting sleep duration. In a rat model of panic vulnerability (involving disinhibition of the PeF OX region) to threatening internal state changes (i.e., intravenous sodium lactate infusion), compound 56 attenuated sodium lactate-induced panic-like behaviors and cardiovascular responses without altering baseline locomotor or autonomic activity. In conclusion, OX1R antagonism represents a novel therapeutic strategy for the treatment of various psychiatric disorders associated with stress or hyperarousal states.

材料
货号
品牌
产品描述

Sigma-Aldrich
1-甲基-2-吡咯烷酮, anhydrous, 99.5%
Sigma-Aldrich
1-甲基-2-吡咯烷酮, ACS reagent, ≥99.0%
Sigma-Aldrich
1-甲基-2-吡咯烷酮, ReagentPlus®, 99%
Sigma-Aldrich
1-甲基-2-吡咯烷酮, suitable for HPLC, ≥99%
Sigma-Aldrich
1-甲基-2-吡咯烷酮, biotech. grade, ≥99.7%
Supelco
1-甲基-2-吡咯烷酮, analytical standard